Literature DB >> 8094091

Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues.

M A Ghatei1, K Takahashi, Y Suzuki, J Gardiner, P M Jones, S R Bloom.   

Abstract

The distribution of a novel neuropeptide, pituitary adenylate cyclase-activating polypeptide (PACAP), was studied in the brain of the rat and man and a variety of other rat tissues using Northern blot hybridization and two radioimmunoassays for PACAP 1-38 and PACAP 1-27. The assay, using PACAP 1-38 as standard and an antibody to PACAP 21-38 and radiolabelled tracer, revealed immunoreactive PACAP in all brain regions examined, with the highest concentrations in the rat being in the hypothalamus, nucleus accumbens and substantia nigra (380 +/- 34, 310 +/- 37 and 346 +/- 30 pmol/g wet tissue, means +/- S.E.M., n = 5 respectively), whilst in man the highest concentrations were found in the pituitary gland (15.8 +/- 4.7 pmol/g). Immunoreactive PACAP 1-38 was also detected in the rat gastrointestinal tract, adrenal gland and testis. The assay using PACAP 1-27 as standard and label and an antibody to PACAP 1-27 detected immunoreactive PACAP only in the rat hypothalamus (12.6 +/- 1.8 pmol/g wet tissue, n = 5). PACAP mRNA of approximately 2.7 kb in size was detectable in all brain regions of both rat and man, and its distribution paralleled that of the immunoreactive peptide. Gel permeation chromatography of different regions of human and rat hypothalamus, and also rat spinal cord and small intestine, showed a broad immunoreactive peak corresponding to PACAP 1-38. Fast protein liquid chromatography (FPLC) resolved this peak into two immunoreactive peaks, the majority eluting in the position of synthetic PACAP 1-38.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094091     DOI: 10.1677/joe.0.1360159

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  42 in total

1.  Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP.

Authors:  Henrik Winther Schytz; Helle Holst; Lars Arendt-Nielsen; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2010-05-09       Impact factor: 7.277

Review 2.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Authors:  Anthony J Harmar; Jan Fahrenkrug; Illana Gozes; Marc Laburthe; Victor May; Joseph R Pisegna; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

4.  Augmented cystine-glutamate exchange by pituitary adenylate cyclase-activating polypeptide signaling via the VPAC1 receptor.

Authors:  Jon M Resch; Rebecca Albano; Xiaoqian Liu; Julie Hjelmhaug; Doug Lobner; David A Baker; Sujean Choi
Journal:  Synapse       Date:  2014-08-06       Impact factor: 2.562

Review 5.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

6.  Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP).

Authors:  H Hashimoto; N Shintani; K Tanaka; W Mori; M Hirose; T Matsuda; M Sakaue; J Miyazaki; H Niwa; F Tashiro; K Yamamoto; K Koga; S Tomimoto; A Kunugi; S Suetake; A Baba
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 7.  PACAP: A regulator of mammalian reproductive function.

Authors:  Stephen J Winters; Joseph P Moore
Journal:  Mol Cell Endocrinol       Date:  2020-06-17       Impact factor: 4.102

8.  High-resolution characterization of a PACAP-EGFP transgenic mouse model for mapping PACAP-expressing neurons.

Authors:  Michael C Condro; Anna Matynia; Nicholas N Foster; Yukio Ago; Abha K Rajbhandari; Christina Van; Bhavaani Jayaram; Sachin Parikh; Anna L Diep; Eileen Nguyen; Victor May; Hong-Wei Dong; James A Waschek
Journal:  J Comp Neurol       Date:  2016-06-03       Impact factor: 3.215

9.  C-terminal amidation of PACAP-38 and PACAP-27 is dispensable for biological activity at the PAC1 receptor.

Authors:  Andrew C Emery; Ryan A Alvarez; Philip Abboud; Wenqin Xu; Craig D Westover; Maribeth V Eiden; Lee E Eiden
Journal:  Peptides       Date:  2016-03-11       Impact factor: 3.750

10.  Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas.

Authors:  H Oka; L Jin; J C Reubi; X Qian; B W Scheithauer; K Fujii; T Kameya; R V Lloyd
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.